<DOC>
	<DOCNO>NCT02096263</DOCNO>
	<brief_summary>The purpose study assess immunogenicity safety GSK Biologicals ' Infanrix hexa vaccine administer healthy infant primary vaccination 2 , 4 6 month age , co-administered Prevnar Rotarix booster dose GSK Biologicals ' Infanrix Hiberix vaccines 15-18 month age .</brief_summary>
	<brief_title>Study Determine Immunogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ; Infanrix Hexa 2 , 4 6 Months Age Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects ' parent ( ) / LAR ( ) , opinion investigator , comply , requirement protocol . A male female , include , 6 12 week age time first vaccination . Born fullterm ( i.e . gestation period 37 week less 42 complete week [ 259 293 day ] ) . Written inform consent obtain parent ( ) /LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Infants receive previous dose hepatitis B vaccine receive 1 dose hepatitis B vaccine administer least 30 day prior enrolment . Child care Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug since birth . For corticosteroid , mean prednisone ≥ 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Planned administration/administration vaccine foreseen study protocol within period start 30 day first vaccination 30 day Dose 3 ( Epoch 001 , primary vaccination ) 30 day booster Dose 4 30 day booster Dose 4 ( Epoch 002 , booster vaccination ) , i.e . end study : Inactivated influenza hepatitis A vaccine allow throughout study . Routine administration ( ) vaccine allow 30 day last dose primary vaccination 30 day booster dose postbooster blood sampling . Routine administration measlesmumpsrubella vaccine , varicella , pneumococcal vaccine allow 30 day last dose primary vaccine 30 day booster dose postbooster blood sampling , well accord recommend immunization schedule US . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . History Hib , diphtheria , tetanus , pertussis , pneumococcal , rotavirus , poliovirus hepatitis B diseases . Previous vaccination Hib , diphtheria , tetanus , pertussis , pneumococcus , rotavirus and/or poliovirus ; one previous dose hepatitis B vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine ( include yeast ) . Hypersensitivity latex . Major congenital defect serious chronic illness . History neurological disorder include seizure . Administration immunoglobulins and/or blood product since birth plan administration study period . History intussusception uncorrected congenital malformation gastrointestinal tract would predispose infant intussusception . History Severe Combined Immunodeficiency Disease ( SCID ) . Acute disease and/or fever time enrolment . Fever define temperature ≥38.0°C /100.4°F route . The preferred route record temperature study rectal Epoch 001 axillary Epoch 002 . Subjects minor illness ( mild diarrhea , mild upper respiratory infection ) without fever may , enrol discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Infanrix Hexa</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Infants</keyword>
	<keyword>Safety</keyword>
</DOC>